# EDGAR Filing Document

**Accession Number:** 0001736730
**File Stem:** 0001736730-26-000004
**Filing Date:** 2026-1
**Character Count:** 6615
**Document Hash:** 32f472f5a4105106730ce13da777c7f1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001736730-26-000004.hdr.sgml**: 20260109

**ACCESSION NUMBER**: 0001736730-26-000004

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 35

**CONFORMED PERIOD OF REPORT**: 20260109

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260109

**DATE AS OF CHANGE**: 20260109

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Camp4 Therapeutics Corp
- **CENTRAL INDEX KEY:** 0001736730
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42365
- **FILM NUMBER:** 26523452

**BUSINESS ADDRESS:**
- **STREET 1:** ONE KENDALL SQUARE
- **STREET 2:** BUILDING 1400 WEST, 3RD FLOOR
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139
- **BUSINESS PHONE:** 617-651-8867

**MAIL ADDRESS:**
- **STREET 1:** ONE KENDALL SQUARE
- **STREET 2:** BUILDING 1400 WEST, 3RD FLOOR
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139

?xml version='1.0' encoding='ASCII'? camp-20260109

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM 8-K**

**CURRENT REPORT** 

**Pursuant to Section 13 or 15(d)** 

**of the Securities Exchange Act of 1934** 

**Date of Report (Date of earliest event reported): January 9, 2026**

**CAMP4 THERAPEUTICS CORPORATION**

**(Exact name of registrant as specified in its charter)** 

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-42365** | **81-1152476** |
| **(State or other jurisdiction<br>of incorporation)** | **(Commission<br>File Number)** | **(IRS Employer<br>Identification No.)** |
| **One Kendall Square**<br>**Building 1400 West, 3rd Floor**<br>**Cambridge, MA** | **One Kendall Square**<br>**Building 1400 West, 3rd Floor**<br>**Cambridge, MA** | **02139** |
| **(Address of principal executive offices)** | **(Address of principal executive offices)** | **(Zip Code)** |

---

**(Registrant's telephone number, including area code): (617) 651-8867**

**Not Applicable** 

**(Former name or former address, if changed since last report)** 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

---

| |
|:---|
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |

---

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>Symbol(s)** | **Name of each exchange<br>on which registered** |
| **Common Stock, par value $0.0001 per share** | **CAMP** | **The Nasdaq Global Market** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ⌧

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

**Item 7.01 Regulation FD Disclosure.**

From time to time, CAMP4 Therapeutics Corporation (the "<u>Company</u>") presents and/or distributes slides and presentations to the investment community to provide updates and summaries of its business. On January 9, 2026, the Company updated its corporate presentation, which is available on the "Investors" section of the Company's website at https://investors.camp4tx.com. This presentation is also furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 and Exhibit 99.1 attached hereto is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "<u>Exchange Act</u>") or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | <u>[Corporate presentation, dated January 2026.](exhibit991-january 2026co.htm)</u> |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| **CAMP4 THERAPEUTICS CORPORATION** | **CAMP4 THERAPEUTICS CORPORATION** |
| By: | /s/ Josh Mandel-Brehm |
|  | Name: Josh Mandel-Brehm |
|  | Title: President and Chief Executive Officer |

---

Date: January 9, 2026

## Exhibit 99.1

![](exhibit991-january 2026co001.jpg)

------

![](exhibit991-january 2026co002.jpg)

------

![](exhibit991-january 2026co003.jpg)

------

![](exhibit991-january 2026co004.jpg)

------

![](exhibit991-january 2026co005.jpg)

------

![](exhibit991-january 2026co006.jpg)

------

![](exhibit991-january 2026co007.jpg)

------

![](exhibit991-january 2026co008.jpg)

------

![](exhibit991-january 2026co009.jpg)

------

![](exhibit991-january 2026co010.jpg)

------

![](exhibit991-january 2026co011.jpg)

------

![](exhibit991-january 2026co012.jpg)

------

![](exhibit991-january 2026co013.jpg)

------

![](exhibit991-january 2026co014.jpg)

------

![](exhibit991-january 2026co015.jpg)

------

![](exhibit991-january 2026co016.jpg)

------

![](exhibit991-january 2026co017.jpg)

------

![](exhibit991-january 2026co018.jpg)

------

![](exhibit991-january 2026co019.jpg)

------

![](exhibit991-january 2026co020.jpg)

------

![](exhibit991-january 2026co021.jpg)

------

![](exhibit991-january 2026co022.jpg)

------